ICER identifies most significant 2020 US drug price hikes not supported by new clinical evidence

ICER

16 November 2021 - Out of 10 identified drugs that had substantial 2020 price increases net of rebates on top of already high current spending, seven were not supported by new clinical evidence; net price increases on these seven drugs cost Americans an additional $1.67 billion in annual drug spend, of which nearly $1.4 billion was due to a single drug alone: Humira.

The Institute for Clinical and Economic Review today published its latest report on unsupported price increases of prescription drugs in the United States.

Read ICER Announcement

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Pricing